65 Results for "

VEGFR2-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (65)

65 Results for "VEGFR2-IN-2" in MCE Product Catalog:

Cat. No.: HY-147133
CAS No.: 737818-56-3
Purity:  99.64%
Target:  

VEGFR

Research Areas:  

Cancer

VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC50 of 19.32 nM. VEGFR2-IN-2 can be used for researching
loading...
    loading...
32
32 Publications Verification
Cat. No.: HY-12686
CAS No.: 253863-19-3
Purity:  99.30%
Synonyms: FR148083; L783279; LL-Z 1640-2
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-10260
CAS No.: 443913-73-3
Purity:  99.95%
Synonyms: ZD6474
Vandetanib (D6474) is a potent, orally active, and blood-brain-barrier penetrate inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-10203
CAS No.: 212141-54-3
Purity:  99.93%
Synonyms: PTK787; ZK-222584; CGP-79787
Target:  

VEGFR

Research Areas:  

Cancer

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-12018
CAS No.: 212141-51-0
Purity:  99.68%
Synonyms: PTK787 dihydrochloride; ZK-222584 dihydrochloride; CGP-797870 dihydrochloride
Vatalanib dihydrochloride (PTK787 dihydrochloride) is a BBB-permeable VEGFR2/KDR inhibitor with an IC50 of 37 nM.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112306
CAS No.: 1442472-39-0
Purity:  98.21%
Synonyms: DCC-2618
Research Areas:  

Cancer

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108628
CAS No.: 251356-45-3
Purity:  99.36
Target:  

PDGFR

Research Areas:  

Cancer

SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0563
CAS No.: 72-48-0
Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and VEGFR2/eNOS pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1663
CAS No.: 272121-15-0
Target:  

VEGFR

Research Areas:  

Others

ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)
loading...
    loading...
Cat. No.: HY-P5438
Research Areas:  

Others

Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
loading...
    loading...
Cat. No.: HY-119487
CAS No.: 1895957-18-2
MMPP is an orally active inhibitor of STAT3 and VEGFR2, as well as an activator of PPARγ. MMPP blocks the VEGFR2/AKT/ERK/NF-κB signaling pathway to inhibit angiogenesis. MMPP inhibits ferroptosis and inflammation, and alleviates sepsis-induced myocardial injury. MMPP induces G1-phase cell cycle arrest and apoptosis, and inhibits the growth of non-small cell lung cancer (NSCLC) and solid tumors. MMPP promotes adipogenesis and glucose uptake. MMPP can be used in research related to NSCLC, type 2 diabetes and myocardial injury .
loading...
    loading...
Cat. No.: HY-112462
CAS No.: 443798-55-8
Purity:  99.69%
Target:  

CDK

Research Areas:  

Cancer

Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective Cdk1/cyclin B and Cdk2/cyclin A inhibitor of with IC50s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC50 of 32 nM), GSK-3β (IC50 of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC50s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively .
loading...
    loading...
Cat. No.: HY-116116
CAS No.: 1032265-57-8
Purity:  96.20%
Synonyms: SIM010603
Target:  

c-Kit RET VEGFR

Research Areas:  

Cancer

Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
loading...
    loading...
Cat. No.: HY-146369
CAS No.: 2353417-85-1
Target:  

PROTACs VEGFR

Research Areas:  

Cancer

PROTAC VEGFR-2 degrader-2 is a VEGFR-2 (KDR) PROTAC degrader with weak inhibitory activity against VEGFR-2 (IC50 > 1 μM). It is applicable to the research of cancer-related pathological angiogenesis .
loading...
    loading...
Cat. No.: HY-106374
CAS No.: 673478-49-4
Target:  

VEGFR

Research Areas:  

Cancer

Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .
loading...
    loading...
Cat. No.: HY-161995
Research Areas:  

Cancer

FGFR1/VEGFR2-IN-2 (compound 6l) is a VEGFR2/FGFR1 dual inhibitor. The IC50 values for VEGFR2 and FGFR1 are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC50 values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC50 of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC50 for MCF-7 cell line exceeds 100 µM, and the IC50 for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .
loading...
    loading...
Cat. No.: HY-146368
CAS No.: 2601594-19-6
Target:  

PROTACs VEGFR

Research Areas:  

Cancer

PROTAC VEGFR-2 degrader-1 is a VEGFR-2-targeting PROTAC with >1 μM IC50 against VEGFR-2, >100 μM IC50 against endothelial cell proliferation, and no significant cytotoxicity against embryonic kidney cells. PROTAC VEGFR-2 degrader-1 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-10260B
CAS No.: 524722-52-9
Synonyms: ZD6474 hydrochloride
Target:  

VEGFR Autophagy Apoptosis

Research Areas:  

Cancer

Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
loading...
    loading...
Cat. No.: HY-155758
CAS No.: 2971782-66-6
Research Areas:  

Cancer

hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
loading...
    loading...
Cat. No.: HY-112337
CAS No.: 288144-20-7
Target:  

VEGFR PDGFR

Research Areas:  

Cancer

VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC50 value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC50 of 920 nM .
loading...
    loading...